Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02933320 | BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia | completed | Phase 1 / Phase 2 | 14 | Cancer Research UKOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT02612779 | A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide. | completed | Phase 2 | 74 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 2, 2021 |
| clinicaltrials |
| NCT04439240 | Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) | completed | Phase 2 | 52 | National Cancer Institute (NCI)NIH | 1 | Jun 29, 2021 | clinicaltrials |
| NCT02424968 | CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma | completed | Phase 2 | 18 | Robert LowskyOTHER | 1 | Jun 24, 2021 | clinicaltrials |
| NCT01643408 | A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy | completed | Phase 2 | 30 | Jazz PharmaceuticalsINDUSTRY | 2 | Jun 23, 2021 | clinicaltrials |
| NCT01592981 | Randomised Trial in Waldenstrom's Macroglobulinaemia(R2W) | completed | Phase 2 | 60 | University College, LondonOTHER | 1 | Jun 18, 2021 | clinicaltrials |
| NCT02703779 | Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM) | completed | Phase 2 | 101 | Siddhartha GangulyOTHER | 1 | Jun 18, 2021 | clinicaltrials |
| NCT02499081 | UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment | completed | Phase 2 | 20 | University of ArkansasOTHER | 1 | Jun 11, 2021 | clinicaltrials |
| NCT02420223 | Study of Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in HCT Recipients | completed | Phase 2 | 25 | Medical College of WisconsinOTHER | 1 | Jun 7, 2021 | clinicaltrials |
| NCT03259529 | Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL(BeGeRN) | completed | Phase 1 / Phase 2 | 30 | St. Petersburg State Pavlov Medical UniversityOTHER | 1 | Jun 7, 2021 | clinicaltrials |
| NCT00151203 | Phase II Study of Biaxin, Revlimid, and Dexamethasone for Untreated Multiple Myeloma | completed | Phase 2 | 50 | Weill Medical College of Cornell UniversityOTHER | 1 | May 27, 2021 | clinicaltrials |
| NCT00702052 | Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy(PILLAR-1) | completed | Phase 2 | 58 | Novartis PharmaceuticalsINDUSTRY | 1 | May 25, 2021 | clinicaltrials |
| NCT03239392 | A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL | completed | Phase 1 / Phase 2 | 50 | Bioniz TherapeuticsINDUSTRY | 1 | May 25, 2021 | clinicaltrials |
| NCT00538733 | Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma(T-BiRD) | completed | Phase 2 | 26 | Weill Medical College of Cornell UniversityOTHER | 1 | May 24, 2021 | clinicaltrials |
| NCT01234766 | Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma(Fol-BRITe) | completed | Phase 2 | 39 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT03892421 | Outpatient Administration of R-DHAP in Relapsed/Refractory Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 22 | La Raza Medical CenterOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT01018979 | Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients | completed | Phase 2 | 19 | GPCR Therapeutics, Inc.INDUSTRY | 1 | May 11, 2021 | clinicaltrials |
| NCT02841033 | Daratumumab for the Treatment of Patients With AL Amyloidosis | completed | Phase 1 / Phase 2 | 22 | Boston Medical CenterOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT01363128 | Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | completed | Phase 2 | 72 | M.D. Anderson Cancer CenterOTHER | 1 | May 3, 2021 | clinicaltrials |
| NCT00981708 | Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL) | completed | Phase 1 / Phase 2 | 37 | University of AthensOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT01046006 | Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia | completed | Phase 2 | 59 | Meletios A. DimopoulosOTHER | 3 | Apr 30, 2021 | clinicaltrials |
| NCT01497496 | Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | completed | Phase 2 | 29 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 27, 2021 | clinicaltrials |
| NCT01177735 | Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma | completed | Phase 2 | 71 | University of ArkansasOTHER | 1 | Apr 22, 2021 | clinicaltrials |
| NCT01458288 | A Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 Alone or in Combination With G-CSF in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease | completed | Phase 2 | 12 | GPCR Therapeutics, Inc.INDUSTRY | 1 | Apr 19, 2021 | clinicaltrials |
| NCT02104427 | PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients | completed | Phase 2 | 12 | GPCR Therapeutics, Inc.INDUSTRY | 1 | Apr 19, 2021 | clinicaltrials |
| NCT02545907 | A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis(CATALYST) | completed | Phase 1 / Phase 2 | 10 | University College, LondonOTHER | 1 | Apr 15, 2021 | clinicaltrials |
| NCT01045460 | Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma(aMILs) | completed | Phase 2 | 36 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 9, 2021 | clinicaltrials |
| NCT03292406 | A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)(CTCL) | completed | Phase 2 | 86 | Galderma R&DINDUSTRY | 3 | Apr 8, 2021 | clinicaltrials |
| NCT04439214 | Testing Nivolumab as a Potential Targeted Treatment in Cancers With Mismatch Repair Deficiency (MATCH-Subprotocol Z1D) | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Apr 6, 2021 | clinicaltrials |
| NCT00773838 | Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095) | completed | Phase 2 | 143 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 1, 2021 | clinicaltrials |
| NCT03262389 | Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma | completed | Phase 2 | 10 | Michael C Roarke, MDOTHER | 1 | Mar 16, 2021 | clinicaltrials |
| NCT01402284 | Carfilzomib, Lenalidomide, and Dexamethasone in New Multiple Myeloma Patients | completed | Phase 2 | 45 | National Cancer Institute (NCI)NIH | 1 | Mar 2, 2021 | clinicaltrials |
| NCT02677155 | Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma(Lymvac-2) | completed | Phase 2 | 10 | Oslo University HospitalOTHER | 1 | Mar 1, 2021 | clinicaltrials |
| NCT02273739 | Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation | completed | Phase 1 / Phase 2 | 21 | CelgeneINDUSTRY | 2 | Feb 23, 2021 | clinicaltrials |
| NCT02059239 | Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma | completed | Phase 1 / Phase 2 | 34 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT02078102 | A Phase II Trial Using Meloxicam Plus Filgrastim in Patients With Multiple Myeloma and Non-Hodgkin's Lymphoma | completed | Phase 2 | 38 | Sherif S. FaragOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT00489203 | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 140 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT00936611 | LBH589 in Relapsed or Relapsed and Refractory Waldenstrom's Macroglobulinemia | completed | Phase 2 | 39 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 28, 2021 | clinicaltrials |
| NCT01380106 | Study to Evaluate Two Lenalidomide Dose Regimens With Low Dose Dexamethasone for the Treatment Relapsed Multiple Myeloma | completed | Phase 2 | 33 | Boston VA Research Institute, Inc.OTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT02910063 | Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL | completed | Phase 2 / Phase 3 | 41 | AmgenINDUSTRY | 8 | Jan 13, 2021 | clinicaltrials |
| NCT00621244 | A Study of Oral LBH589 in Adult Patients With Advanced Hematological Malignancies | completed | Phase 1 / Phase 2 | 175 | Novartis PharmaceuticalsINDUSTRY | 3 | Jan 5, 2021 | clinicaltrials |
| NCT01930162 | Safety and Tolerability of HSC835 in Patients With Hematological Malignancies Undergoing Single Umbilical Cord Blood Transplant(UCBT) | completed | Phase 2 | 9 | Novartis PharmaceuticalsINDUSTRY | 1 | Jan 5, 2021 | clinicaltrials |
| NCT01474681 | Safety and Tolerability of HSC835 in Patients With Hematological Malignancies | completed | Phase 1 / Phase 2 | 27 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 30, 2020 | clinicaltrials |
| NCT00002348 | A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkin's Lymphoma | completed | Phase 2 | — | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT01058434 | Safety and Efficacy of TKI258 in Relapsed or Refractory Multiple Myeloma Patients, Who Are With or Without t(4;14) Chromosomal Translocation | completed | Phase 2 | 43 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 19, 2020 | clinicaltrials |
| NCT00670592 | Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies | completed | Phase 1 / Phase 2 | 111 | Novartis PharmaceuticalsINDUSTRY | 11 | Dec 17, 2020 | clinicaltrials |
| NCT00708292 | A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma. | completed | Phase 1 / Phase 2 | 29 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 17, 2020 | clinicaltrials |
| NCT01302886 | Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma | completed | Phase 2 | 41 | Novartis PharmaceuticalsINDUSTRY | 3 | Dec 17, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Jul 8, 2021source: clinicaltrials